Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 1.00 |
| ▸ | CTSL | P07711 | 5/20 | 0.75 |
| ▸ | CTSB | P07858 | 2/20 | 0.75 |
| ▸ | CTSF | Q9UBX1 | 2/20 | 0.75 |
| ▸ | CTSV | O60911 | 1/20 | 0.75 |
| ▸ | CTSS | P25774 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23874957 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL4987203 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL4590757 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL4590785 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL5742250 | 0.91 | CTSK (0.85) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL4986789 | 0.90 | CTSK (0.82) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL2155710 | 0.90 | CTSK (0.82) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL21690159 | 0.90 | CTSK (0.82) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL2155451 | 0.90 | CTSK (0.82) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL23875152 | 0.90 | CTSK (0.82) | CTSKCTSLCTSBCTSFCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317077-A1 | Crystalline Forms of N1-(1-Cyanocycloproply)-N2-((1S)-1-{4'-[(1R-2,2-Difluoro-1-Hydroxyethyl]Biphenyl-4-YL}-2,2,2-Trifluoroethyl)-4-Fluoro-L-Leucinamide | INTERVET INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210300863-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | INTERVET INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210300863-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | INTERVET INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3830075-A1 | CRYSTALLINE FORMS OF N1-(1-CYANOCYCLOPROPLY)-N2-((1S)-1-{4'-[(1R-2,2-DIFLUORO-1-HYDROXYETHYL]BIPHENYL-4-YL}-2,2,2-TRIFLUOROETHYL)-4-FLUORO-L-LEUCINAMIDE | Intervet International B.V. (NL) | 2021-06-09 | — | — | EP | disclosed |
| EP-3830074-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | Intervet International B.V. (NL) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020025748-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | INTERVET INTERNATIONAL B.V. (NL) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020025748-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | INTERVET INTERNATIONAL B.V. (NL) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020025749-A1 | CRYSTALLINE FORMS OF N1-(1-CYANOCYCLOPROPLY)-N2-((1S)-1-{4'-[(1R-2,2-DIFLUORO-1-HYDROXYETHYL]BIPHENYL-4-YL}-2,2,2-TRIFLUOROETHYL)-4-FLUORO-L-LEUCINAMIDE | INTERVET INTERNATIONAL B.V. (NL) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300863-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | CTSB, CTSF, CTSZ | CTSK 8/4885CTSL 11/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.